MYRIAD GENETICS INC.

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

11 7 2024 09:00:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

09 7 2024 09:00:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Earns 2024 Great Place To Work® Certification™

02 7 2024 09:00:00 提供 Nasdaq GlobeNewswire

Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election

24 6 2024 16:05:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

11 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen

04 6 2024 09:00:00 提供 Nasdaq GlobeNewswire

Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

03 6 2024 16:05:00 提供 Nasdaq GlobeNewswire

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

30 5 2024 17:55:30 提供 Nasdaq GlobeNewswire

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

23 5 2024 18:00:00 提供 Nasdaq GlobeNewswire

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

16 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

07 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

07 5 2024 09:00:00 提供 Nasdaq GlobeNewswire

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

30 4 2024 16:05:00 提供 Nasdaq GlobeNewswire

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

17 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

16 4 2024 09:15:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

09 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

21 3 2024 21:40:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

20 3 2024 16:05:00 提供 Nasdaq GlobeNewswire

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

27 2 2024 16:05:01 提供 Nasdaq GlobeNewswire

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

27 2 2024 09:15:00 提供 Nasdaq GlobeNewswire